Prolactinoma

Table of Contents

  1. What a Prolactinoma Is
  2. Prolactin Physiology and Hyperprolactinemia
  3. Symptoms in Women
  4. Symptoms in Men
  5. Mass Effects — Visual Field Defects and Headaches
  6. Diagnosis
  7. Treatment — Dopamine Agonists
  8. Surgery, Radiation, and Special Situations
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What a Prolactinoma Is

A prolactinoma is a benign (non-cancerous) tumor of the anterior pituitary gland that produces excess prolactin. It is the most common type of functioning pituitary tumor, accounting for approximately 40% of all pituitary adenomas. Prevalence is estimated at 10–50 per 100,000 people. Prolactinomas are classified by size: microprolactinoma (<10 mm diameter) and macroprolactinoma (≥10 mm). Microprolactinomas are more common in women; macroprolactinomas are more common in men and are typically diagnosed later due to more insidious symptom onset. Malignant prolactin-secreting carcinomas are exceedingly rare (<0.2% of cases).

Back to Table of Contents

Prolactin Physiology and Hyperprolactinemia

Prolactin is secreted by lactotroph cells of the anterior pituitary. Its primary physiological role is initiating and maintaining lactation. Unique among pituitary hormones, prolactin is under tonic inhibitory control by dopamine (from the hypothalamus via the tuberoinfundibular pathway); loss of dopamine inhibition permits prolactin excess. Elevated prolactin suppresses the hypothalamic-pituitary-gonadal axis by inhibiting gonadotropin-releasing hormone (GnRH) pulsatility, leading to reduced luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Normal serum prolactin: women <25 ng/mL; men <15 ng/mL. Prolactinoma typically causes levels >100 ng/mL (often >200 ng/mL for macroprolactinomas). Mild elevations (25–100 ng/mL) have a broader differential including medications, hypothyroidism, renal failure, and physiologic stress.

Back to Table of Contents

Symptoms in Women

Hyperprolactinemia in premenopausal women presents as the classic triad: (1) Amenorrhea or oligomenorrhea — disruption of the normal luteinizing hormone/follicle-stimulating hormone surge. (2) Galactorrhea — spontaneous or expressible milky nipple discharge (in 50–80% of cases). (3) Infertility — anovulation secondary to suppressed gonadotropins. Additional features: decreased libido, vaginal dryness, dyspareunia, osteopenia/osteoporosis (from chronic estrogen deficiency). Postmenopausal women may have few symptoms from hyperprolactinemia itself (ovarian function already absent) and present primarily with tumor mass effects.

Back to Table of Contents

Symptoms in Men

Hyperprolactinemia is often underdiagnosed in men because galactorrhea is uncommon and the gonadal axis symptoms develop insidiously. Presenting features include: erectile dysfunction and decreased libido (from hypogonadotropic hypogonadism), infertility (oligospermia or azoospermia), gynecomastia (rare, caused by reduced testosterone and relative estrogen excess), decreased bone mineral density. Men typically present with larger tumors (macroprolactinomas) at diagnosis, as the gonadal symptoms are less specific and often attributed to other causes.

Back to Table of Contents

Mass Effects — Visual Field Defects and Headaches

Large prolactinomas (macroprolactinomas) may compress adjacent structures. The optic chiasm lies directly above the pituitary fossa; upward extension compresses it, producing bitemporal hemianopsia — loss of peripheral (temporal) vision in both eyes, classically starting with the superior temporal fields. Cavernous sinus invasion causes cranial nerve palsies (CN III, IV, VI — ophthalmoplegia, ptosis, diplopia). Headache from dural stretch is common. Pituitary apoplexy (hemorrhage or infarction into the tumor) is a rare emergency causing sudden severe headache, visual loss, and altered consciousness. Gadolinium-enhanced magnetic resonance imaging (MRI) of the pituitary is the imaging modality of choice.

Back to Table of Contents

Diagnosis

Serum prolactin: The screening test. A single fasting measurement is usually sufficient; a stressful blood draw can cause a mild, passing rise, which a sample taken after rest avoids. Very high prolactin (>500 ng/mL) is virtually diagnostic of macroprolactinoma. The "hook effect": extremely high prolactin levels can paradoxically appear normal or low on immunoassay — diluting the sample step by step (serial dilutions) reveals the true level when magnetic resonance imaging shows a large tumor with a disproportionately "normal" prolactin. Secondary causes are ruled out with: thyroid-stimulating hormone (TSH) (hypothyroidism raises thyrotropin-releasing hormone (TRH), stimulating prolactin), medication review (dopamine antagonists: antipsychotics, metoclopramide, domperidone, some antidepressants; proton pump inhibitors; opioids), renal function (impaired clearance), and pregnancy (beta human chorionic gonadotropin (beta-hCG) test). Pituitary magnetic resonance imaging: characterizes tumor size, invasion, and relationship to optic chiasm.

Back to Table of Contents

Treatment — Dopamine Agonists

Dopamine agonists (DAs) are the first-line treatment for virtually all prolactinomas, including macroprolactinomas, because they suppress prolactin production and directly shrink tumor volume in 80–90% of patients. Cabergoline (preferred): Half-life ~65 hours; dosed twice weekly (0.25–3 mg/week; the U.S. label starts at 0.25 mg twice weekly and lists 1 mg twice weekly as its maximum recommended dose). Superior efficacy and tolerability vs. bromocriptine. In a 1994 trial of 459 women whose periods had stopped because of high prolactin, prolactin returned to normal in 83% on cabergoline vs 59% on bromocriptine, 72% vs 52% ovulated or became pregnant, and only 3% stopped cabergoline because of side effects vs 12% for bromocriptine. In a 1999 series of 455 patients, cabergoline normalized prolactin in 86% and the tumor shrank in 67%; the median dose was 1.0 mg per week at the start and could be lowered to 0.5 mg per week once prolactin was controlled. Side effects: nausea, dizziness, orthostatic hypotension, constipation; impulse control disorders — a 2025 meta-analysis of 8 observational studies (858 patients) linked dopamine agonists in prolactinoma to more impulse control disorders overall (risk ratio 1.71), particularly hypersexuality (risk ratio 2.61) and punding (repetitive, purposeless tasks; risk ratio 2.31), with no significant difference for pathological gambling, binge eating or compulsive shopping. Heart valves: the U.S. cabergoline label lists a history of heart-valve disorders or pericardial fibrosis, and uncontrolled hypertension, as contraindications; it calls for a heart evaluation including an echocardiogram (heart ultrasound) before starting and an echocardiogram every 6 to 12 months during treatment, and says cabergoline is stopped if a new valve disease is diagnosed. A 2018 meta-analysis of 13 case-control studies of people taking cabergoline for at least 6 months for high prolactin found more tricuspid regurgitation (a leaky tricuspid valve; odds ratio 3.74) than in controls, none of it diagnosed because of symptoms, and no significant increase in any other valve problem; the authors called its clinical significance unclear. Bromocriptine: Older, shorter-acting (dosed daily), more nausea; preferred in pregnancy (more safety data). Contraindication: uncontrolled hypertension. Goal: normalize prolactin AND restore gonadal function. After 2 years of normal prolactin + tumor shrinkage, a supervised trial off the drug is a recognized option. A 2010 meta-analysis (19 studies, 743 patients) found that prolactin stayed normal after withdrawal in 21% overall — 21% of microprolactinomas, 16% of macroprolactinomas and 32% of people with idiopathic hyperprolactinemia — and that success was most likely when cabergoline had been used for at least 2 years.

Back to Table of Contents

Surgery, Radiation, and Special Situations

Transsphenoidal surgery (TSS): Indicated for DA-intolerant/resistant patients, acute visual loss from mass effect not responding to DAs rapidly, or pituitary apoplexy. Cure rates: ~75–90% for microprolactinomas, ~40–50% for macroprolactinomas. Risks: cerebrospinal fluid (CSF) leak, meningitis, hypopituitarism, permanent diabetes insipidus. Radiation: Rarely needed; reserved for malignant or highly aggressive tumors not responding to DAs or surgery; takes years to achieve prolactin normalization. Pregnancy: Bromocriptine is preferred over cabergoline for planned conception (more safety data). Prolactinoma may enlarge during pregnancy (especially macroprolactinomas); monthly visual field monitoring if not resected. TRH effects: Thyrotropin-releasing hormone directly stimulates both thyroid-stimulating hormone and prolactin; untreated hypothyroidism causes secondary hyperprolactinemia reversible with thyroid hormone replacement, which is why thyroid-stimulating hormone is part of every work-up. Current guidance: in 2023 the Pituitary Society published an international consensus statement on prolactinoma covering dopamine-agonist withdrawal, when surgery is chosen (including medical therapy before surgery), radiation, pregnancy and fertility, children and adolescents, people with psychiatric illness, postmenopausal women, transgender individuals and people with chronic kidney disease; it follows the society's 2006 guideline.

Back to Table of Contents

Key Research Papers

  1. Melmed S et al., 2011 — Endocrine Society clinical practice guideline: Diagnosis and treatment of hyperprolactinemia. J Clin Endocrinol Metab. — PubMed PMID: 21296991
  2. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF, 1994 — A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 331(14):904–9. — PubMed PMID: 7915824
  3. Molitch ME, 2017 — Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 317(5):516–524. — PubMed PMID: 28170483
  4. Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM, 2010 — Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 95(1):43–51. — PubMed PMID: 19880787
  5. Gillam MP, Molitch ME, Lombardi G, Colao A, 2006 — Advances in the treatment of prolactinomas. Endocr Rev. 27(5):485–534. — PubMed PMID: 16705142
  6. Schlechte JA, 2003 — Clinical practice. Prolactinoma. N Engl J Med. 349(21):2035–41. — PubMed PMID: 14627789
  7. Verhelst J, Abs R, Maiter D, et al., 1999 — Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 84(7):2518–22. — PubMed PMID: 10404830
  8. Casanueva FF, Molitch ME, Schlechte JA, et al., 2006 — Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 65(2):265–73. — PubMed PMID: 16886971
  9. Petersenn S, Fleseriu M, Casanueva FF, et al., 2023 — Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 19(12):722–740. — PubMed PMID: 37670148
  10. Klibanski A, 2010 — Clinical practice. Prolactinomas. N Engl J Med. 362(13):1219–26. — PubMed PMID: 20357284
  11. Vilar L et al. — PubMed search: cabergoline prolactinoma remission withdrawal — Prolactinoma treatment with cabergoline. — Search PubMed
  12. Bronstein MD et al. — PubMed search: prolactinoma pregnancy bromocriptine cabergoline — Prolactinomas in pregnancy. — Search PubMed
  13. Penchev P, Milanova-Ilieva D, Gaydarski L, et al., 2025 — Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis. J Clin Neurosci. 138:111363. — PubMed PMID: 40480033
  14. Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM, 2018 — A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J Clin Endocrinol Metab. — PubMed PMID: 30215804
  15. U.S. National Library of Medicine, DailyMed — Cabergoline tablets, prescribing information (contraindications; warnings: cardiac valvulopathy and pericardial fibrosis). — DailyMed label

Back to Table of Contents

Connections

Research Papers — PubMed Searches

Back to Table of Contents